IRIS
CIANI, ORIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.602
NA - Nord America 4.764
AS - Asia 3.305
SA - Sud America 395
AF - Africa 41
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 21
Totale 15.154
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.489
IT - Italia 2.821
CN - Cina 1.269
IE - Irlanda 1.111
SG - Singapore 833
GB - Regno Unito 492
UA - Ucraina 423
DE - Germania 400
HK - Hong Kong 358
RU - Federazione Russa 354
BR - Brasile 345
CA - Canada 238
SE - Svezia 227
FI - Finlandia 224
TR - Turchia 205
VN - Vietnam 164
FR - Francia 131
NL - Olanda 89
KR - Corea 77
IN - India 74
ID - Indonesia 68
IL - Israele 66
BG - Bulgaria 56
CZ - Repubblica Ceca 53
KZ - Kazakistan 49
BE - Belgio 36
MX - Messico 32
ES - Italia 27
AT - Austria 25
AU - Australia 22
PL - Polonia 22
RO - Romania 21
IR - Iran 18
EU - Europa 17
CH - Svizzera 15
JP - Giappone 15
BD - Bangladesh 14
PT - Portogallo 14
AE - Emirati Arabi Uniti 12
PK - Pakistan 12
DK - Danimarca 11
EC - Ecuador 11
IQ - Iraq 11
MA - Marocco 10
AR - Argentina 9
CL - Cile 8
NO - Norvegia 8
VE - Venezuela 8
EG - Egitto 7
LT - Lituania 7
LV - Lettonia 7
ZA - Sudafrica 7
HU - Ungheria 6
PH - Filippine 6
UZ - Uzbekistan 6
AZ - Azerbaigian 5
CO - Colombia 5
GR - Grecia 5
KE - Kenya 5
KG - Kirghizistan 5
PE - Perù 5
LA - Repubblica Popolare Democratica del Laos 4
LU - Lussemburgo 4
OM - Oman 4
SA - Arabia Saudita 4
TH - Thailandia 4
TW - Taiwan 4
LK - Sri Lanka 3
TN - Tunisia 3
AL - Albania 2
AM - Armenia 2
BO - Bolivia 2
BY - Bielorussia 2
EE - Estonia 2
GE - Georgia 2
NG - Nigeria 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PA - Panama 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
TJ - Tagikistan 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AD - Andorra 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
CD - Congo 1
CI - Costa d'Avorio 1
CM - Camerun 1
DZ - Algeria 1
GH - Ghana 1
JO - Giordania 1
KH - Cambogia 1
KW - Kuwait 1
MO - Macao, regione amministrativa speciale della Cina 1
Totale 15.147
Salva come PNG Salva come JPEG
Città #
Dublin 1.107
Chandler 673
Milan 626
Hefei 553
Singapore 479
Ashburn 375
Hong Kong 356
Jacksonville 335
Beijing 260
Ann Arbor 258
Southend 215
Rome 203
Toronto 192
New York 154
The Dalles 151
Redmond 149
Dearborn 146
Helsinki 141
Dong Ket 130
Wilmington 116
Houston 114
Lawrence 97
Modena 94
Boston 93
Boardman 84
Los Angeles 82
Munich 79
Seoul 71
Izmir 70
Moscow 69
Jakarta 67
Tel Aviv 65
Naples 59
Frankfurt am Main 52
Redwood City 50
Almaty 49
Mountain View 48
Palombara Sabina 47
Seattle 44
Woodbridge 40
Bologna 36
Fairfield 36
Bari 30
Brussels 30
Lappeenranta 29
Nuremberg 28
Fremont 27
São Paulo 27
Turin 27
Genoa 24
Florence 23
Ottawa 23
Catania 21
Brno 20
Washington 20
San Francisco 19
Assago 18
Dallas 17
Bucharest 16
Council Bluffs 16
Kunming 16
Mexico City 16
Nanjing 16
Chennai 15
Düsseldorf 15
Falkenstein 15
Santa Clara 15
West Jordan 15
Belo Horizonte 14
Guangzhou 14
Trieste 14
Vienna 14
Brescia 13
Brooklyn 13
Jinan 13
Palermo 13
Rio de Janeiro 13
Chicago 12
London 12
Robbiate 12
Amsterdam 11
Napoli 11
Padova 11
Secaucus 11
Tokyo 11
Trento 11
Bergamo 10
Bonndorf 10
Falls Church 10
Hanoi 10
Norwalk 10
Serino 10
Shenyang 10
Torino 10
Venice 10
Darwin 9
Islamabad 9
Monza 9
Nardò 9
Paris 9
Totale 8.961
Salva come PNG Salva come JPEG
Nome #
La funzione di HTA nelle aziende sanitarie italiane: un potenziale ancora inutilizzato? 357
Esiti di salute e performance del Servizio Sanitario Nazionale 357
Prezzi di riferimento per dispositivi medici: criticità, vantaggi e approcci 336
PDTA per la chirurgia bariatrica: l'esperienza di 6 centri italiani 279
Dinamiche economiche e performance del settore dei dispositivi medici in Italia 272
EQ-5D-5L population norms for Italy 266
I dispositivi medici in Italia: un settore, tanti mercati 248
Programma nazionale HTA per dispositivi medici: quali sfide per l’implementazione? 235
Gli esiti di salute del Servizio Sanitario Nazionale 208
Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis 202
De innovatione: the concept of innovation for medical technologies and its implications for healthcare policy-making 193
Surrogate endpoints: a key concept in clinical epidemiology 190
An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration 189
Current and Future Trends in the HTA of Medical Devices 176
Real-world data for the evaluation of transarterial radioembolization versus sorafenib in hepatocellular carcinoma: a cost-effectiveness analysis 176
Gli esiti di salute del Servizio Sanitario Nazionale 176
La dimensione del settore dei dispositivi medici 175
Endpoint surrogati e politiche sanitarie: l’importanza di metodi di validazione adeguati 175
Myth #5: health care is rightly left to the private sector, for the sake of efficiency 174
Establishing a national HTA program for medical devices in Italy: overhauling a fragmented system to ensure value and equal access to new medical technologies 167
A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer 158
Integrating HTA principles into procurement of medical devices: the Italian national HTA programme for medical devices 156
Surrogate endpoints in health technology assessment: an international review of methodological guidelines 148
I processi di valutazione dei dispositivi medici e delle tecnologie sanitarie 144
The Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer 144
An economic perspective on urinary tract infection: the "costs of resignation" 139
A scoping review of core outcome sets and their 'mapping' onto real-world data using prostate cancer as a case study 138
Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses 137
An electronic patient-reported outcome mobile app for data collection in type a hemophilia: design and usability study 137
A bias-adjusted evidence synthesis of RCT and observational data: the case of total hip replacement 135
Valutare l’impatto dell’HTA come strumento di governo dell’innovazione tecnologica: modelli teorici e studi empirici 135
Core outcome set in surgical oncology: why, what and how to measure 134
Patient-reported outcome measures in core outcome sets targeted overlapping domains but through different instruments 133
Measuring value in health care: a comparative analysis of value-based frameworks 130
Distinguishing features in the assessment of mHealth apps 130
Comparing drug and non-drug technologies in comparative effectiveness research 128
Mud-bath therapy in addition to usual care in bilateral knee osteoarthritis: economic evaluation alongside a randomized controlled trial 125
Cost–effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma 125
Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal 124
Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis 121
Broadening the concept of value: a scoping review on the option value of medical technologies 120
Combining tumour response and progression free survival as surrogate endpoints for overall survival in advanced colorectal cancer 118
Diffusion and use of Health Technology Assessment in policy making: what lessons for decentralised healthcare systems? 118
Hospital-based HTA: quale valore per la valutazione delle tecnologie nelle Aziende Sanitarie italiane? 117
European diabetes research and its funding, 2002–2013 117
Time to review the role of surrogate end points in health policy: state of the art and the way forward 115
Il settore dei dispositivi medici in Italia. L’impatto delle politiche pubbliche sulle performance delle imprese 114
Development features and study characteristics of mobile health apps in the management of chronic conditions: a systematic review of randomised trials 114
Harnessing digital health technologies during and after the COVID-19 pandemic: context matters 113
La gestione dell'innovazione tecnologica in sanità: analisi e confronto di alcune politiche regionali in Italia 112
Exercise training for chronic heart failure (ExTraMATCH II): why all data are not equal 112
A randomized, open-label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethyl sulfoxide in women with bladder pain syndrome/interstitial cystitis 111
Esiti di salute e performance del Servizio Sanitario Nazionale 111
The rise of rules: will the new regulation of medical devices make us safer? 111
Coverage with evidence development for medical devices in Europe: can practice meet theory? 111
The evaluation of medical devices: are we getting closer to solve the puzzle? A review of recent trends 110
Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study 109
Introduction to economic evaluation and health technology assessment 109
Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges 106
Mapping payment and pricing schemes for health innovation: protocol of a scoping literature review 106
Determinants of demand for total hip and and knee arthroplasty: a systematic literature review 105
Health technology assessment methods guidelines for medical devices: how can we address the gaps? the international federation of medical and biological engineering perspective 105
Cost-effectiveness analysis of oral nutritional supplements with nutritional counselling in head and neck cancer patients undergoing radiotherapy. 105
Non-communicable diseases: mapping research funding organisations, funding mechanisms and research practices in Italy and Germany 103
A more evidence based approach to the use of surrogate end points in policy making 102
Decision uncertainty and value of further research: a case-study in fenestrated endovascular aneurysm repair for complex abdominal aortic aneurysms 102
Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study 101
Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case study for technology appraisal on the basis of surrogate outcomes evidence 101
Validation of exercise capacity as a surrogate endpoint in exercise-based rehabilitation for heart failure: a meta-analysis of randomized controlled trials 101
Value-based healthcare: il nuovo approccio di AIFA alla determinazione multidimensionale del valore 101
Response to COVID-19: was Italy (un)prepared? 99
Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework 98
The impacts of diabetes research from 31 European Countries in 2002 to 2013 98
Assessment of nonfatal myocardial infarction as a surrogate for all-cause and cardiovascular mortality in treatment or prevention of coronary artery disease: a meta-analysis of randomized clinical trials 98
Strumenti a supporto del processo decisionale condiviso in oncologia 97
Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case-control study 97
Corona-regionalism? Differences in regional responses to COVID-19 in Italy 97
Recommendations for developing a lifecycle, multidimensional assessment framework for mobile medical apps 97
Urinary Tract Infections – An Economic Issue 96
Valorizzare gli esiti riferiti dal paziente : opportunità e sfide 95
Surrogate, friend or foe? The need for case studies of the use of surrogate outcomes in cost-effectiveness analyses 95
Quantitative body movement and gesture assessment in ergonomics. 92
Validation of surrogate end points for overall survival in advanced colorectal cancer: a harmonized approach is needed 92
Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer 92
Esiti di salute e performance del Servizio Sanitario Nazionale 91
Health technology assessment of medical devices: a survey of non-European union agencies 91
Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers 90
Esiti di salute e performance del Servizio Sanitario Nazionale 88
Linking the regulatory and reimbursement processes for medical devices: the need for integrated assessments 88
Exercise training for chronic heart failure (ExTraMATCH II): protocol for an individual participant data meta-analysis 86
Impact of exercise-based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: an individual patient data meta-analysis of randomised trials 84
Value lies in the eye of the patients: the why, what, and how of patient-reported outcomes measures 81
Pervasive technology in Neonatal Intensive Care Unit: a prototype for newborns unobtrusive monitoring 80
A call for better reporting of trials using surrogate primary endpoints 79
The role of health technology assessment bodies in shaping drug development 78
An accelerated access pathway for innovative high-risk medical devices under the new European Union Medical Devices and health technology assessment regulations? Analysis and recommendations 76
The Coronavirus pandemic and inequality in Italy 76
The impact of surgical experience in VATS lobectomy on conversion and patient quality of life: results from a comprehensive national video-assisted thoracic surgical database 74
Direct healthcare costs of non-metastatic castration-resistant prostate cancer in Italy 71
Lifecycle evidence requirements for high-risk implantable medical devices: a European perspective 71
Totale 13.199
Salva come PNG Salva come JPEG
Categoria #
all - tutte 77.570
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 77.570
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.291 0 86 33 106 143 91 129 58 156 118 116 255
2021/20221.500 107 220 50 68 140 66 58 233 72 145 143 198
2022/20233.178 202 173 86 266 203 223 83 162 1.398 121 161 100
2023/20242.436 109 142 149 59 258 287 193 324 98 180 303 334
2024/20253.372 108 71 228 172 179 195 276 245 961 384 341 212
2025/20261.235 758 477 0 0 0 0 0 0 0 0 0 0
Totale 15.600